Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16102500 | 0.91 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16094782 | 0.89 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16121742 | 0.87 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16100370 | 0.85 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16103364 | 0.85 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16121735 | 0.84 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16103475 | 0.83 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16121748 | 0.83 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16094726 | 0.81 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL19341983 | 0.81 | RAF1 (1.00) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299367-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2018-03-28 | — | — | EP | claimed |
| CN-108467369-B | Biaryl amide compounds as kinase inhibitors | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2019-04-02 | — | — | US | disclosed |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2019-04-02 | — | — | US | disclosed |
| EP-3299367-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-20170260207-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170260207-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9694016-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-9694016-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-9694016-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| EP-2970216-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151616-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151616-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | RAF1 2/4885BRAF 1/4885 |
| US-20170260207-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | RAF1 2/4885BRAF 1/4885 |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | RAF1 2/4885BRAF 1/4885 |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | RAF1 2/4885BRAF 1/4885 |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | RAF1 2/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.